Privacy·Terms·Disclaimer

Bibliographic data courtesy of the U.S. National Library of Medicine (NLM), sourced from PubMed/MEDLINE.

SciRadar is not affiliated with, endorsed by, or sponsored by NLM or NCBI. Abstracts remain © their respective publishers.

Secondary Malignancy After EBRT: A Closer Look at Absolute Risk and Follow-Up. — SciRadar

Back to results

Clinical genitourinary cancer

Secondary Malignancy After EBRT: A Closer Look at Absolute Risk and Follow-Up.

Ahmet Necati Sanli, Deniz Esin Tekcan Sanli

Published: 202610.1016/j.clgc.2025.102479

No abstract available for this study.